KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Inventory: 2017-2025

Historic Change in Inventory for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $30.8 million.

  • Amneal Pharmaceuticals' Change in Inventory fell 28.52% to $30.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.8 million, marking a year-over-year increase of 16.92%. This contributed to the annual value of $130.5 million for FY2024, which is 3.45% up from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Change in Inventory is $30.8 million, which was up 35.26% from $22.8 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Change in Inventory's 5-year high stood at $52.0 million during Q4 2024, with a 5-year trough of -$16.6 million in Q4 2021.
  • For the 3-year period, Amneal Pharmaceuticals' Change in Inventory averaged around $29.4 million, with its median value being $23.2 million (2024).
  • The largest annual percentage gain for Amneal Pharmaceuticals' Change in Inventory in the last 5 years was 630.13% (2021), contrasted with its biggest fall of 150.30% (2021).
  • Over the past 5 years, Amneal Pharmaceuticals' Change in Inventory (Quarterly) stood at -$16.6 million in 2021, then skyrocketed by 166.57% to $11.1 million in 2022, then skyrocketed by 108.58% to $23.1 million in 2023, then surged by 125.14% to $52.0 million in 2024, then decreased by 28.52% to $30.8 million in 2025.
  • Its Change in Inventory stands at $30.8 million for Q3 2025, versus $22.8 million for Q2 2025 and $13.3 million for Q1 2025.